Cargando…

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights

Receptor tyrosine kinases (RTKs) inhibitors’ activity in advanced osteosarcoma is significant but short-lived. To prevent or at least delay drug resistance, we explored a vertical inhibition by combining drugs acting at different levels of the RTK pathways (pazopanib + trametinib). We studied pazopa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiabotto, Giulia, Grignani, Giovanni, Todorovic, Maja, Martin, Valentina, Centomo, Maria Laura, Prola, Elisa, Giordano, Giorgia, Merlini, Alessandra, Miglio, Umberto, Berrino, Enrico, Napione, Lucia, Isella, Claudio, Capozzi, Federica, Basiricò, Marco, Marsero, Cristina, Gerardi, Ilaria, Venesio, Tiziana, Sangiolo, Dario, Aglietta, Massimo, D’Ambrosio, Lorenzo, Pignochino, Ymera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352822/ https://www.ncbi.nlm.nih.gov/pubmed/32531992 http://dx.doi.org/10.3390/cancers12061519

Ejemplares similares

PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study
por: Pignochino, Ymera, et al.
Publicado: (2021)

DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
por: Merlini, Alessandra, et al.
Publicado: (2022)

EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giordano, Giorgia, et al.
Publicado: (2021)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
por: Mesiano, Giulia, et al.
Publicado: (2018)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
por: Pignochino, Ymera, et al.
Publicado: (2015)

ZnO nanocrystals shuttled by extracellular vesicles as effective Trojan nano-horses against cancer cells
por: Dumontel, Bianca, et al.
Publicado: (2019)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
por: BALL, DOUGLAS W., et al.
Publicado: (2015)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018)

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy
por: Goracci, Martina, et al.
Publicado: (2020)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Exosome-Based Liquid Biopsy Approaches in Bone and Soft Tissue Sarcomas: Review of the Literature, Prospectives, and Hopes for Clinical Application
por: Agnoletto, Chiara, et al.
Publicado: (2023)

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
por: Pignochino, Ymera, et al.
Publicado: (2009)

High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
por: Palmerini, Emanuela, et al.
Publicado: (2020)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
por: Urbonas, V, et al.
Publicado: (2019)

High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients
por: Berrino, E., et al.
Publicado: (2021)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Alpha–fetoprotein elevation in NUT midline carcinoma: a case report
por: D’Ambrosio, Lorenzo, et al.
Publicado: (2017)

Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples
por: Bussolati, Gianni, et al.
Publicado: (2017)

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions
por: Merlini, Alessandra, et al.
Publicado: (2023)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Recent advances in the development of breast cancer vaccines
por: Milani, Andrea, et al.
Publicado: (2014)

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
por: Stella, Giulia M., et al.
Publicado: (2014)

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity
por: Leuci, V., et al.
Publicado: (2016)

Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients
por: Berrino, Enrico, et al.
Publicado: (2021)

The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients
por: Berrino, Enrico, et al.
Publicado: (2022)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer
por: Berrino, Enrico, et al.
Publicado: (2020)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1(+) Chemoresistant Lung Cancer Cells
por: Rotolo, Ramona, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nldn2us3l84e6ikhp65ab3mbvb